Mineralys Therapeutics (MLYS) Scheduled to Post Earnings on Monday

Posted by Defense World Staff on May 8th, 2023

Mineralys Therapeutics (NASDAQ:MLYS – Get Rating) will be posting its quarterly earnings results after the market closes on Monday, May 15th. Analysts expect Mineralys Therapeutics to post earnings of ($0.71) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS – Get Rating) last posted its earnings results on Wednesday, March 15th. The company reported ($1.74) EPS for the quarter. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Mineralys Therapeutics Trading Up 7.0 %

Mineralys Therapeutics stock opened at $15.67 on Monday. Mineralys Therapeutics has a 52 week low of $12.62 and a 52 week high of $21.98. The business’s 50 day moving average price is $15.11.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Credit Suisse Group dropped their target price on shares of Mineralys Therapeutics from $40.00 to $38.00 and set an “outperform” rating on the stock in a research report on Thursday, March 16th. Wells Fargo & Company initiated coverage on shares of Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an “overweight” rating and a $27.00 price target on the stock. Bank of America initiated coverage on shares of Mineralys Therapeutics in a report on Tuesday, March 7th. They issued a “buy” rating and a $39.00 price target on the stock. Guggenheim initiated coverage on shares of Mineralys Therapeutics in a report on Tuesday, March 7th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Mineralys Therapeutics in a report on Tuesday, March 7th. They issued a “buy” rating and a $45.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, Mineralys Therapeutics presently has an average rating of “Buy” and a consensus target price of $36.20.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Ra Capital Management, L.P. bought 1,250,000 shares of the stock in a transaction on Tuesday, February 14th. The shares were acquired at an average price of $16.00 per share, with a total value of $20,000,000.00. Following the acquisition, the director now directly owns 1,867,229 shares of the company’s stock, valued at approximately $29,875,664. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Mineralys Therapeutics news, Director Ra Capital Management, L.P. bought 1,250,000 shares of the stock in a transaction on Tuesday, February 14th. The shares were acquired at an average price of $16.00 per share, with a total value of $20,000,000.00. Following the acquisition, the director now directly owns 1,867,229 shares of the company’s stock, valued at approximately $29,875,664. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Hbm Healthcare Investments (Ca purchased 312,500 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, February 14th. The shares were purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the transaction, the insider now directly owns 3,218,106 shares in the company, valued at $51,489,696. The disclosure for this purchase can be found here. Insiders have acquired 1,568,750 shares of company stock valued at $25,100,000 in the last 90 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mineralys Therapeutics stock. Barclays PLC purchased a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 12,536 shares of the company’s stock, valued at approximately $196,000.

About Mineralys Therapeutics

(Get Rating)

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc is based in RADNOR, Pa.